Action RYTM RHYTHM PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Rhythm Pharmaceuticals, Inc.

Actions

RYTM

US76243J1051

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
53,89 USD +3,83 % Graphique intraday de Rhythm Pharmaceuticals, Inc. +19,92 % +17,23 %
08/07 Rhythm Pharmaceuticals nomme Alastair Garfield au poste de directeur scientifique MT
08/07 Rhythm Pharmaceuticals, Inc. annonce la nomination d'Alastair Garfield au poste de directeur scientifique CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
GL
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
AQ
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
GL
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
AQ
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
AQ
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals : RYTM 1Q2024 vFinal
PU
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
GL
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
GL
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
AQ
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
GL
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
GL
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
GL
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action RYTM
  4. Actualités Rhythm Pharmaceuticals, Inc.
  5. Communiqués